SciELO - Scientific Electronic Library Online

vol.82 número4Un tratamiento “a la carta” para los pacientes con adenocarcinoma pancreáticoRecomendaciones para el tratamiento de la amiloidosis AL índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO


Medicina (Buenos Aires)

versión impresa ISSN 0025-7680versión On-line ISSN 1669-9106


ELBERT, Alicia et al. Renal effects of GLP-1 agonists in type 2 diabetes. Medicina (B. Aires) [online]. 2022, vol.82, n.4, pp.576-590. ISSN 0025-7680.

The prevalence of type 2 diabetes mellitus (DM2) is increasing, generating a great impact both at individual and public health level. Nearly half of the patients with DM2 develop impaired renal function, so nephron-protection is highly important. The robust body of evidence that shifted the therapeutic focus from glycemic to cardio-renal metabolic therapy in DM2 led to the inclusion of new therapies with cardiovascular and renal benefits in international guidelines. Type 1 glucagon (GLP-1) receptor agonists have showed favorable effects on renal function and their potential protective actions are multifactorial, beyond glycemic control. These benefits have been demonstrated in efficacy and safety clini cal studies, as well as in cardiovascular outcomes and real-life studies. This comprehensive review describes the direct and indirect effects of these molecules, as well as evidence obtained from pivotal clinical (LEADER, SUSTAIN 6 and REWIND) and real-life studies demonstrating their beneficial effects on renal function, and also introduces expectations of future results from ongoing studies with renal endpoints.

Palabras clave : GLP-1 receptor agonists; Type 2 diabetes mellitus; Renal outcomes.

        · resumen en Español     · texto en Español     · Español ( pdf )